Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ENLV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ENLV

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Enlivex Therapeutics Ltd

ENLV
Current price
1.16 USD +0.05 USD (+4.50%)
Last closed 1.09 USD
ISIN IL0011319527
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 25 996 392 USD
Yield for 12 month -17.73 %
1Y
3Y
5Y
10Y
15Y
ENLV
21.11.2021 - 28.11.2021

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel. Address: 14 Einstein Street, Ness Ziona, Israel, 7403618

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.00 USD

P/E ratio

Dividend Yield

Financials ENLV

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ENLV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-545 000 USD

Last Year

-835 000 USD

Current Quarter

-36 000 USD

Last Quarter

EBITDA -14 643 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -34.24 %
PEG Ratio
Return On Equity TTM -60.35 %
Wall Street Target Price 10.00 USD
Revenue TTM
Book Value 0.87 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -0.66 USD
Diluted Eps TTM -0.66 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation ENLV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -1.49
Price Book MRQ 1.21

Technical indicators ENLV

For 52 weeks

0.81 USD 1.76 USD
50 Day MA 0.97 USD
Shares Short Prior Month 121 442
200 Day MA 1.16 USD
Short Ratio 1.80
Shares Short 98 582
Short Percent 0.43 %